Profile change history

What changed for Lutetium Lu 177 dotatate?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Lutetium Lu 177 dotatate identity.

42Total events
41Record additions
1Version changes
6Cited source years

Before and after

Preserved version changes

Record updated

ClinicalTrials.gov record NCT05278208

ClinicalTrials.gov posted a newer version of NCT05278208, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
After
PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

Cited source date

Before
2026-07-20
After
2026-11-16

Cited source records

Before
ctg-observation-nct05278208-2026-07-20-294c4af79959
After
ctg-observation-nct05278208-2026-07-20-294c4af79959-r2

Headline citations

Before
ctg-observation-nct05278208-2026-07-20-294c4af79959
After
ctg-observation-nct05278208-2026-07-20-294c4af79959-r2

Summary citations

Before
ctg-observation-nct05278208-2026-07-20-294c4af79959
After
ctg-observation-nct05278208-2026-07-20-294c4af79959-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959-r2]

Source snapshot commitment

Before
27842e169ac0417a0d1e79de9ecf095381201b52a0342053ddcf98a7ea8d7793
After
caf11e90bc5b4e47237f7e29c972eafdab923d3b708553f0c1c65a7b25eae129

Collection chronology

Evidence added to PeptideScanner

Browse all 41 connected records →

Showing the latest 41 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 16, 2026.

Record added

ClinicalTrials.gov record NCT01578239

PeptideScanner retained ClinicalTrials.gov record NCT01578239 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
April 4, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03325816

PeptideScanner retained ClinicalTrials.gov record NCT03325816 at 2026-11-16T01:36:36.861Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
March 16, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03457948

PeptideScanner retained ClinicalTrials.gov record NCT03457948 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
August 28, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03590119

PeptideScanner retained ClinicalTrials.gov record NCT03590119 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-11-08, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 8, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03971461

PeptideScanner retained ClinicalTrials.gov record NCT03971461 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
September 29, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03972488

PeptideScanner retained ClinicalTrials.gov record NCT03972488 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
January 21, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04082520

PeptideScanner retained ClinicalTrials.gov record NCT04082520 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
October 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04234568

PeptideScanner retained ClinicalTrials.gov record NCT04234568 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04261855

PeptideScanner retained ClinicalTrials.gov record NCT04261855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
March 27, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04529044

PeptideScanner retained ClinicalTrials.gov record NCT04529044 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
June 5, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04665739

PeptideScanner retained ClinicalTrials.gov record NCT04665739 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04711135

PeptideScanner retained ClinicalTrials.gov record NCT04711135 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
February 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04750954

PeptideScanner retained ClinicalTrials.gov record NCT04750954 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04954820

PeptideScanner retained ClinicalTrials.gov record NCT04954820 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
June 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05142696

PeptideScanner retained ClinicalTrials.gov record NCT05142696 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
August 19, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05178693

PeptideScanner retained ClinicalTrials.gov record NCT05178693 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05247905

PeptideScanner retained ClinicalTrials.gov record NCT05247905 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
October 20, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05278208

PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
July 20, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05583708

PeptideScanner retained ClinicalTrials.gov record NCT05583708 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
September 25, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05691465

PeptideScanner retained ClinicalTrials.gov record NCT05691465 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05724108

PeptideScanner retained ClinicalTrials.gov record NCT05724108 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
July 31, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05773274

PeptideScanner retained ClinicalTrials.gov record NCT05773274 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06016855

PeptideScanner retained ClinicalTrials.gov record NCT06016855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
June 24, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06326190

PeptideScanner retained ClinicalTrials.gov record NCT06326190 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
June 15, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06395402

PeptideScanner retained ClinicalTrials.gov record NCT06395402 at 2026-11-16T01:36:36.861Z. Its registry update date was 2025-07-22, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
July 22, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06955169

PeptideScanner retained ClinicalTrials.gov record NCT06955169 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 9, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07910760

PeptideScanner retained ClinicalTrials.gov record NCT07910760 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 2, 2026
Evidence lane
Clinical trials
Record added

Federal Register notice 2022-25549

The Federal Register published notice 2022-25549, attributed to FDA and its parent HHS department, on 2022-11-23. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Lutetium Lu 177 dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 23, 2022
Evidence lane
Regulatory
Record added

Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung.

PubMed lists PMID 32616557 in Journal for immunotherapy of cancer as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-07 (month precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
September 20, 2021
Evidence lane
Literature metadata
Record added

Lutetium Lu-177 Dotatate Flare Reaction.

PubMed lists PMID 33490736 in Advances in radiation oncology as Journal Article, with publication-date metadata of 2020-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
April 20, 2022
Evidence lane
Literature metadata
Record added

A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH).

PubMed lists PMID 36550428 in BMC cancer as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2022-12-22 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE.

PubMed lists PMID 37111596 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2023-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
May 1, 2023
Evidence lane
Literature metadata
Record added

Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case.

PubMed lists PMID 37184824 in European journal of drug metabolism and pharmacokinetics as Journal Article, with publication-date metadata of 2023-05-15 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 9, 2026
Evidence lane
Literature metadata
Record added

177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor.

PubMed lists PMID 37883194 in Clinical nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2023-10-23 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 9, 2026
Evidence lane
Literature metadata
Record added

Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®.

PubMed lists PMID 37930495 in EJNMMI radiopharmacy and chemistry as Journal Article, with publication-date metadata of 2023-11-06 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 10, 2023
Evidence lane
Literature metadata
Record added

Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.

PubMed lists PMID 38451361 in Journal of neuro-oncology as Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 1, 2026
Evidence lane
Literature metadata
Record added

Hematological toxicities with Lutathera® for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA.

PubMed lists PMID 38849643 in Endocrine as Letter, with publication-date metadata of 2024-06-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
October 10, 2026
Evidence lane
Literature metadata
Record added

FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto.

PubMed lists PMID 41935511 in Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
September 16, 2026
Evidence lane
Literature metadata